{"gene":"RHO","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1984,"finding":"The human rhodopsin gene was isolated and fully sequenced, revealing a coding region interrupted by four introns at positions analogous to bovine rhodopsin, and a deduced amino acid sequence of 348 residues that is 93.4% homologous to bovine rhodopsin.","method":"Gene isolation and nucleotide sequencing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing of isolated gene, foundational structural characterization","pmids":["6589631"],"is_preprint":false},{"year":1988,"finding":"Two adjacent cysteine residues (Cys-322 and Cys-323) in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated, identifying a post-translational lipid modification site on the protein.","method":"Covalent coupling to CPG-thiol glass, CNBr peptide separation and chemical characterization","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical identification of palmitoylation sites by peptide fractionation","pmids":["3350146"],"is_preprint":false},{"year":1990,"finding":"A C→A transversion in codon 23 of the rhodopsin gene (Pro23His substitution) was identified as a mutation causing one form of autosomal dominant retinitis pigmentosa, establishing RHO as the disease gene.","method":"PCR-based mutation screening in patients vs. controls","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — mutation identified in 17/148 unrelated patients, absent in 102 controls, correlated with conserved residue across opsins","pmids":["2137202"],"is_preprint":false},{"year":1990,"finding":"Three additional rhodopsin mutations (two in codon 347, one in codon 58) were found to cause autosomal dominant retinitis pigmentosa, and together with Pro23His account for ~18% of ADRP cases, with all patients showing abnormal rod function on ERG.","method":"Mutation screening of rhodopsin gene exons in 150 unrelated ADRP patients","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple mutations identified and correlated with disease phenotype across large patient cohort","pmids":["2215617"],"is_preprint":false},{"year":1990,"finding":"Mutations in the second and third cytoplasmic loops of rhodopsin (CD2 and EF1 mutants) allow normal transducin (Gt) binding but prevent Gt release in the presence of GTP, while a mutation at the cytoplasmic border of TM3 (CD1) prevents Gt binding entirely, demonstrating that distinct cytoplasmic loop regions are required for Gt activation vs. binding.","method":"Site-directed mutagenesis, flash photolysis to monitor Gt binding and dissociation, GTPase activity assay","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro mutagenesis with direct functional assays for G protein binding and activation","pmids":["2218504"],"is_preprint":false},{"year":1991,"finding":"Systematic screening identified 13 different point mutations at 12 amino acid positions in the rhodopsin gene among 161 ADRP patients, with mutation presence/absence correlating with disease status in 174/179 individuals tested in 17 families.","method":"PCR and denaturing gradient gel electrophoresis screening","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — large-scale family cosegregation analysis across multiple independent pedigrees","pmids":["1862076"],"is_preprint":false},{"year":1991,"finding":"A comprehensive survey of all rhodopsin gene exons in 150 ADRP patients identified 17 different mutations (all single amino acid substitutions), with class II mutations clustering in transmembrane and extracellular domains, establishing a mutational spectrum and preliminary structure-function map.","method":"Complete exon sequencing of rhodopsin gene in ADRP patients","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — comprehensive mutational survey with cosegregation analysis","pmids":["1833777"],"is_preprint":false},{"year":1992,"finding":"Mutation of Lys-296 (retinal attachment site) or Glu-113 (Schiff base counterion) in rhodopsin causes constitutive activation of opsin (transducin activation in the absence of chromophore and light), establishing that a salt bridge between these two residues constrains rhodopsin to an inactive conformation.","method":"Site-directed mutagenesis, transducin activation assay in vitro","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assay with mutagenesis defining catalytic mechanism; K296E also found in RP patients","pmids":["1356370"],"is_preprint":false},{"year":1992,"finding":"Transgenic mice expressing the human P23H rhodopsin mutation develop photoreceptor degeneration in all three lines, with severity correlated with transgene expression level, establishing the pathogenicity of this mutation in vivo; overexpression of wild-type human rod opsin also causes degeneration.","method":"Transgenic mouse generation, histology, ERG, immunostaining","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — multiple transgenic lines with dose-dependent phenotype and functional validation by ERG","pmids":["1418997"],"is_preprint":false},{"year":1993,"finding":"Biochemical analysis of 21 ADRP rhodopsin mutants revealed two classes: class I mutants (G51V, V345M, P347S) resemble wild-type in yield, retinal regenerability, and plasma membrane localization; class II mutants are reduced in yield, fail to regenerate with 11-cis-retinal, and accumulate in the endoplasmic reticulum, with class II amino acids located in transmembrane and extracellular domains.","method":"Site-directed mutagenesis, transfection of HEK293S cells, immunofluorescence, retinal regeneration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — systematic mutagenesis with multiple biochemical readouts defining two mechanistic classes","pmids":["8253795"],"is_preprint":false},{"year":1993,"finding":"The GABA rho2 receptor was characterized, showing that it forms homooligomeric GABA-gated channels when expressed in Xenopus oocytes with pharmacological profiles similar to rho1 but with slower responses and higher potency for most agonists; this gene is distinct from the rhodopsin RHO gene.","method":"Xenopus oocyte expression, electrophysiology","journal":"European journal of pharmacology","confidence":"Low","confidence_rationale":"EXCLUDED — GABA rho2 is a different gene, not rhodopsin RHO","pmids":["8386671"],"is_preprint":false},{"year":1993,"finding":"The Ala292Glu rhodopsin mutation causes congenital stationary night blindness by anomalously activating transducin in the absence of chromophore (constitutive activation), while retaining normal light-dependent transducin activation, defining a mechanism for night blindness distinct from RP mutations.","method":"In vitro transducin activation assay with recombinant mutant opsin","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution assay directly measuring transducin activation with and without chromophore","pmids":["8358437"],"is_preprint":false},{"year":1994,"finding":"The G90D rhodopsin mutation causes congenital night blindness by constitutively activating opsin; Asp-90 can substitute for the Schiff base counterion Glu-113, demonstrating proximity of these residues in 3D structure and a common mechanism for constitutively activating mutations that disrupt the Lys296–Glu113 salt bridge.","method":"Site-directed mutagenesis, transducin activation assay, suppressor mutation analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and suppressor analysis revealing molecular mechanism","pmids":["8107847"],"is_preprint":false},{"year":1994,"finding":"A rhodopsin carboxy-terminus truncation mutation (Q344ter) does not impair transducin activation or rhodopsin kinase phosphorylation in vitro, but causes mislocalization of mutant protein to the plasma membrane of photoreceptor cell bodies in transgenic mice rather than outer segments, establishing that the C-terminus contains a signal required for outer segment targeting.","method":"Site-directed mutagenesis, transducin activation assay, transgenic mice, immunofluorescence confocal microscopy, electrophysiology","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro functional assays plus in vivo transgenic localization studies with multiple methods","pmids":["7523628"],"is_preprint":false},{"year":1996,"finding":"Transgenic mice expressing the P347S rhodopsin mutation show photoreceptor degeneration correlated with transgene expression, with accumulation of rhodopsin-laden extracellular vesicles near the inner/outer segment junction, indicating defective vectorial transport of rhodopsin to outer segment disc membranes as the pathogenic mechanism.","method":"Transgenic mice, ERG, immunocytochemistry, confocal microscopy, ultrastructural immunocytochemistry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple lines with graded expression, ultrastructural and immunocytochemical localization","pmids":["8943080"],"is_preprint":false},{"year":2002,"finding":"The P23H rhodopsin mutation causes the protein to form high-molecular-weight oligomeric aggregates and accumulate in aggresomes (pericentriolar inclusion bodies requiring intact microtubules) in transfected cells; the aggregated protein is targeted for degradation by the ubiquitin-proteasome system, and its expression impairs overall proteasome function.","method":"Transfection, FRET, immunofluorescence, proteasome inhibitor treatment, dominant-negative ubiquitin co-expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including FRET for aggregation detection, functional proteasome impairment assay","pmids":["12091393"],"is_preprint":false},{"year":2003,"finding":"The conserved NPxxY(x)5,6F motif in rhodopsin TM7 connects to cytoplasmic helix 8; the interaction between Y306 and F313 within this motif must be disrupted during Meta I/Meta II transition, as mutations eliminating this interaction rescue Meta II formation in 9-demethyl-retinal-reconstituted rhodopsin. However, these mutations dramatically reduce G protein activation, indicating helix 8 realignment is separately required for proper signal transduction.","method":"Site-directed mutagenesis (Ala replacements, disulfide bond engineering), UV-vis spectroscopy, transducin activation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus disulfide trapping with multiple functional readouts","pmids":["12601165"],"is_preprint":false},{"year":2005,"finding":"Rhodopsin mutations causing ADRP can be classified into biochemical groups based on protein folding, retinal binding, membrane localization, and post-translational processing, with distinct gain-of-function (constitutive activation, dominant-negative) mechanisms underlying different mutations.","method":"Systematic review and classification of published biochemical and cellular studies","journal":"Trends in molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 — synthesis of prior experimental data; no new primary experiments","pmids":["15823756"],"is_preprint":false},{"year":2009,"finding":"Activation of rhodopsin is mediated by photoisomerization of retinal triggering stepwise rearrangement of TM5-TM6 that opens a cytoplasmic crevice; the C-terminus of the Gα subunit of transducin binds into this crevice, and the Gα C-terminal helix acts as a transmission rod to the nucleotide binding site to catalyze GDP/GTP exchange.","method":"Integration of biochemical studies with high-resolution 3D crystal structures","journal":"Trends in biochemical sciences","confidence":"High","confidence_rationale":"Tier 1 — structural and biochemical synthesis defining G protein activation mechanism","pmids":["19836958"],"is_preprint":false},{"year":2014,"finding":"Molecular dynamics simulations of rhodopsin (and other GPCRs) reveal that a hydrophobic layer near the NPxxY motif acts as a gate that opens to form a continuous internal water channel only upon receptor activation; the conserved Y7.53 undergoes transitions between three conformations representing inactive, G-protein-activated, and metastates.","method":"Molecular dynamics simulation validated against available crystal structures","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 4 — computational simulation, consistent with structural data but not directly experimentally validated","pmids":["25203160"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of constitutively active human rhodopsin bound to pre-activated mouse visual arrestin (determined by serial femtosecond X-ray laser crystallography) reveals that rhodopsin uses TM7 and helix 8 to recruit arrestin, and arrestin adopts a ~20° inter-domain rotation that opens a cleft to accommodate a short helix from the second intracellular loop of rhodopsin.","method":"Serial femtosecond X-ray laser (XFEL) crystallography, biochemical mutagenesis validation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with extensive biochemical and mutagenesis validation","pmids":["26200343"],"is_preprint":false},{"year":2017,"finding":"XFEL crystal structure of the rhodopsin-arrestin complex shows that phosphorylated C-terminal tail residues T336 and S338 of rhodopsin, together with E341, form an intermolecular β-sheet with N-terminal β-strands of arrestin through electrostatic interactions with three positively charged pockets, defining a phosphorylation code for arrestin recruitment common to multiple GPCRs.","method":"X-ray free electron laser (XFEL) crystallography, phosphorylation site identification, mutagenesis and validation across multiple GPCRs","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — high-resolution structure with mutagenesis and cross-GPCR validation","pmids":["28753425"],"is_preprint":false},{"year":2018,"finding":"Cryo-EM structure of activated human rhodopsin bound to inhibitory Gi protein reveals that major interactions are mediated by the C-terminal helix of the Giα subunit wedged into the cytoplasmic cavity of the TM helix bundle and contacting the N-terminus of helix 8 of rhodopsin; structural comparison with Gs-bound β2AR and arrestin-bound rhodopsin identifies unique structural signatures distinguishing Gs, Gi, and arrestin coupling.","method":"Cryo-electron microscopy structure determination, structural comparison","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with comparative structural analysis across multiple GPCR signaling complexes","pmids":["29899450"],"is_preprint":false}],"current_model":"Rhodopsin (RHO) is a light-sensitive GPCR in rod photoreceptors that is constrained in an inactive conformation by a Lys296–Glu113 salt bridge; photoisomerization of 11-cis-retinal disrupts this salt bridge and triggers stepwise TM5–TM6 rearrangement that opens a cytoplasmic crevice to catalyze GDP/GTP exchange in transducin (Gαt), with phosphorylation of C-terminal residues T336/S338 by rhodopsin kinase then recruiting arrestin via an intermolecular β-sheet interaction that terminates G protein signaling; mutations in its transmembrane and extracellular domains cause misfolding and ER retention (class II ADRP), while C-terminal mutations disrupt outer segment targeting, and certain mutations constitutively activate the receptor to cause night blindness."},"narrative":{"teleology":[{"year":1984,"claim":"Cloning and sequencing of the human RHO gene established its exon-intron organization and 348-residue primary structure, providing the molecular foundation for all subsequent structure–function studies.","evidence":"Gene isolation and full nucleotide sequencing of human rhodopsin","pmids":["6589631"],"confidence":"High","gaps":["No functional assays performed","Three-dimensional structure unknown at this stage"]},{"year":1988,"claim":"Identification of palmitoylation at Cys-322/Cys-323 revealed a post-translational lipid anchor that tethers the cytoplasmic tail to the membrane, defining a structural feature later recognized as helix 8.","evidence":"Biochemical peptide fractionation and chemical characterization of bovine rhodopsin C-terminal fragment","pmids":["3350146"],"confidence":"High","gaps":["Functional consequence of palmitoylation for signaling or trafficking not tested","Human rhodopsin palmitoylation inferred from bovine data"]},{"year":1990,"claim":"Discovery of the Pro23His mutation and additional mutations at codons 58 and 347 as causes of autosomal dominant retinitis pigmentosa established RHO as the first identified ADRP gene and raised the question of how diverse mutations in a single receptor cause photoreceptor degeneration.","evidence":"PCR-based mutation screening in ADRP patient cohorts with cosegregation analysis","pmids":["2137202","2215617"],"confidence":"High","gaps":["Molecular mechanism of degeneration for each mutation unknown","No biochemical classification of mutation effects yet"]},{"year":1990,"claim":"Mutagenesis of cytoplasmic loops demonstrated that distinct regions mediate transducin binding versus GDP/GTP exchange, dissecting the receptor–G protein coupling interface for the first time.","evidence":"Site-directed mutagenesis with flash photolysis and GTPase activity assays in vitro","pmids":["2218504"],"confidence":"High","gaps":["Structural basis of loop–transducin contact not resolved","Role of helix 8 and C-terminus in G protein coupling not addressed"]},{"year":1992,"claim":"Demonstrating that disruption of the Lys296–Glu113 salt bridge causes constitutive transducin activation established the molecular constraint that holds dark-state rhodopsin inactive—a foundational insight for understanding both normal activation and gain-of-function disease mutations.","evidence":"Site-directed mutagenesis of K296 and E113 with in vitro transducin activation assays","pmids":["1356370"],"confidence":"High","gaps":["Structural dynamics of salt bridge breakage during activation not visualized","Whether other interhelical contacts also restrain activation not addressed"]},{"year":1992,"claim":"Transgenic P23H mice reproduced human ADRP with dose-dependent photoreceptor degeneration, providing the first in vivo validation that a specific rhodopsin mutation is sufficient to cause the disease.","evidence":"Multiple transgenic mouse lines with graded expression; histology and ERG","pmids":["1418997"],"confidence":"High","gaps":["Cellular mechanism of degeneration (misfolding, ER stress, proteasome impairment) not yet identified","Wild-type overexpression also caused degeneration, complicating interpretation"]},{"year":1993,"claim":"Systematic biochemical analysis of 21 ADRP mutants established two mechanistic classes: class II mutations (transmembrane/extracellular) cause misfolding and ER retention, while class I mutations (cytoplasmic/C-terminal) fold normally but affect function or trafficking, providing a framework that guided subsequent therapeutic strategies.","evidence":"HEK293S cell expression, retinal regeneration assay, immunofluorescence localization","pmids":["8253795"],"confidence":"High","gaps":["Whether class II mutants trigger UPR or specific degradation pathways not tested","In vivo relevance of class assignments not yet confirmed"]},{"year":1993,"claim":"The A292E mutation was shown to constitutively activate transducin without chromophore, explaining congenital stationary night blindness as a gain-of-function mechanism distinct from the loss-of-function RP mutations.","evidence":"In vitro transducin activation assay with recombinant A292E opsin ± chromophore","pmids":["8358437"],"confidence":"High","gaps":["Structural basis of A292E constitutive activity not resolved","Whether other night blindness mutations share this mechanism not fully explored"]},{"year":1994,"claim":"G90D was found to constitutively activate opsin by functionally substituting for the Glu-113 counterion, unifying the night-blindness mutations under a common salt-bridge disruption mechanism; separately, Q344ter truncation demonstrated that the C-terminus contains an outer segment targeting signal.","evidence":"Mutagenesis with suppressor analysis for G90D; transgenic mice with confocal immunofluorescence for Q344ter","pmids":["8107847","7523628"],"confidence":"High","gaps":["Identity of the C-terminal targeting machinery unknown","Whether mislocalization alone is sufficient for degeneration not established"]},{"year":1996,"claim":"P347S transgenic mice showed rhodopsin-laden extracellular vesicles at the inner/outer segment junction, directly demonstrating that C-terminal mutations cause defective vectorial transport rather than protein misfolding.","evidence":"Transgenic mice with ultrastructural immunocytochemistry and confocal microscopy","pmids":["8943080"],"confidence":"High","gaps":["Molecular machinery mediating C-terminal-dependent transport not identified","Contribution of vesicle shedding to photoreceptor death not quantified"]},{"year":2002,"claim":"P23H rhodopsin was shown to form high-molecular-weight aggregates in aggresomes and impair proteasome function, identifying proteostasis collapse as a specific toxic mechanism for class II misfolding mutants.","evidence":"FRET-based aggregation detection, immunofluorescence of aggresomes, proteasome activity assays in transfected cells","pmids":["12091393"],"confidence":"High","gaps":["Whether proteasome impairment is the primary cause of photoreceptor death in vivo not established","Role of autophagy as alternative clearance pathway not tested"]},{"year":2003,"claim":"Mutagenesis of the NPxxY(x)5,6F motif revealed that the Y306–F313 interaction must break during Meta II formation but is separately required for G protein activation, defining helix 8 realignment as a distinct mechanistic step in receptor signaling.","evidence":"Alanine mutagenesis and disulfide trapping with UV-vis spectroscopy and transducin activation assays","pmids":["12601165"],"confidence":"High","gaps":["Dynamics of helix 8 motion not captured at atomic resolution","Whether helix 8 rearrangement also controls arrestin recruitment not tested"]},{"year":2009,"claim":"Integration of crystal structures and biochemical data defined the complete activation cascade: retinal photoisomerization drives TM5–TM6 opening of a cytoplasmic crevice into which the Gα C-terminal helix inserts as a transmission rod to the nucleotide binding site, resolving the structural mechanism of GDP/GTP exchange.","evidence":"Synthesis of high-resolution crystal structures with biochemical activation studies","pmids":["19836958"],"confidence":"High","gaps":["Full dynamics of the activation intermediate states not captured","Structural basis of kinetic selectivity for transducin over other G proteins not resolved"]},{"year":2015,"claim":"The first crystal structure of the rhodopsin–arrestin complex revealed that TM7 and helix 8 form the primary arrestin recruitment interface, and arrestin undergoes a ~20° inter-domain rotation to accommodate rhodopsin's second intracellular loop, establishing the structural basis of signal termination.","evidence":"Serial femtosecond XFEL crystallography with mutagenesis validation","pmids":["26200343"],"confidence":"High","gaps":["Whether the pre-activated arrestin used captures the physiological binding mode debated","Membrane context and lipid contributions absent"]},{"year":2017,"claim":"Higher-resolution XFEL structure defined a phosphorylation code: phospho-T336, phospho-S338, and E341 of rhodopsin form an intermolecular β-sheet with three positively charged arrestin pockets, a mechanism generalizable across GPCRs.","evidence":"XFEL crystallography with phosphorylation-site identification and cross-GPCR mutagenesis validation","pmids":["28753425"],"confidence":"High","gaps":["Full combinatorial phosphorylation code (barcode) not exhaustively mapped","Kinetic contribution of individual phosphorylation sites to arrestin affinity in vivo not determined"]},{"year":2018,"claim":"Cryo-EM structure of activated rhodopsin bound to Gi revealed unique structural signatures distinguishing Gi, Gs, and arrestin coupling, addressing the long-standing question of how a single GPCR architecture selects among effectors.","evidence":"Cryo-EM structure determination with comparative structural analysis","pmids":["29899450"],"confidence":"High","gaps":["Transducin (Gt)-specific complex structure not yet determined at comparable resolution","How membrane composition modulates coupling selectivity remains unclear"]},{"year":null,"claim":"Key unresolved questions include the high-resolution structure of the native rhodopsin–transducin complex in a membrane environment, the precise contribution of each C-terminal phosphorylation site to arrestin affinity in vivo, and the mechanistic link between P23H aggregation/proteasome impairment and photoreceptor cell death.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No native rhodopsin–transducin complex structure at high resolution","In vivo phosphorylation barcode not fully mapped","Causal pathway from protein aggregation to rod cell death not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,7,11,12,18,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,7,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[9,13,14]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[9,15]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[13,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,7,11,12,16,18,20,21,22]},{"term_id":"R-HSA-9709957","term_label":"Sensory Perception","supporting_discovery_ids":[7,11,12,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,5,6,8,9,15]}],"complexes":[],"partners":["GNAT1","SAG","GRK1","GNB1","GNAI1"],"other_free_text":[]},"mechanistic_narrative":"Rhodopsin (RHO) is a light-activated G protein–coupled receptor in rod photoreceptors that initiates the visual transduction cascade by coupling photon absorption to transducin activation. The 11-cis-retinal chromophore is held inactive by a Lys296–Glu113 salt bridge; photoisomerization breaks this constraint, driving stepwise TM5–TM6 rearrangement that opens a cytoplasmic crevice into which the Gαt C-terminal helix inserts to catalyze GDP/GTP exchange [PMID:1356370, PMID:19836958, PMID:29899450]. Signal termination proceeds through rhodopsin kinase phosphorylation of C-terminal residues T336/S338, which form an intermolecular β-sheet with arrestin N-terminal β-strands, defining a conserved phosphorylation code for arrestin recruitment [PMID:28753425, PMID:26200343]. Mutations in RHO cause autosomal dominant retinitis pigmentosa—with class II transmembrane/extracellular-domain mutations producing ER-retained misfolded protein, C-terminal mutations disrupting outer segment targeting, and constitutively activating mutations (e.g., A292E, G90D) causing congenital night blindness [PMID:2137202, PMID:8253795, PMID:8358437, PMID:7523628]."},"prefetch_data":{"uniprot":{"accession":"P08100","full_name":"Rhodopsin","aliases":["Opsin-2"],"length_aa":348,"mass_kda":38.9,"function":"Photoreceptor required for image-forming vision at low light intensity (PubMed:7846071, PubMed:8107847). Required for photoreceptor cell viability after birth (PubMed:12566452, PubMed:2215617). Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins (PubMed:26200343, PubMed:28524165, PubMed:28753425, PubMed:8107847). Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling (PubMed:26200343, PubMed:28524165)","subcellular_location":"Membrane; Cell projection, cilium, photoreceptor outer segment","url":"https://www.uniprot.org/uniprotkb/P08100/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RHO","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RHO","total_profiled":1310},"omim":[{"mim_id":"621527","title":"TRANSMEMBRANE PROTEIN 145; TMEM145","url":"https://www.omim.org/entry/621527"},{"mim_id":"621466","title":"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2KK; CMT2KK","url":"https://www.omim.org/entry/621466"},{"mim_id":"621436","title":"MICROCEPHALY, PROGRESSIVE, WITH SIMPLIFIED GYRAL PATTERN AND CEREBELLAR HYPOPLASIA; MGCH","url":"https://www.omim.org/entry/621436"},{"mim_id":"621331","title":"BRAIN SMALL VESSEL DISEASE 5 WITH OSTEOPOROSIS; BSVD5","url":"https://www.omim.org/entry/621331"},{"mim_id":"621280","title":"RETINITIS PIGMENTOSA 100; RP100","url":"https://www.omim.org/entry/621280"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"retina","ntpm":3767.6}],"url":"https://www.proteinatlas.org/search/RHO"},"hgnc":{"alias_symbol":["OPN2","CSNBAD1"],"prev_symbol":["RP4"]},"alphafold":{"accession":"P08100","domains":[{"cath_id":"1.20.1070.10","chopping":"25-325","consensus_level":"high","plddt":91.9446,"start":25,"end":325}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08100","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08100-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08100-F1-predicted_aligned_error_v6.png","plddt_mean":88.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RHO","jax_strain_url":"https://www.jax.org/strain/search?query=RHO"},"sequence":{"accession":"P08100","fasta_url":"https://rest.uniprot.org/uniprotkb/P08100.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08100/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08100"}},"corpus_meta":[{"pmid":"12478284","id":"PMC_12478284","title":"Rho GTPases in cell biology.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12478284","citation_count":3906,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16212495","id":"PMC_16212495","title":"Rho GTPases: biochemistry and biology.","date":"2005","source":"Annual review of cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16212495","citation_count":2432,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11683406","id":"PMC_11683406","title":"Rho GTPases and cell migration.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11683406","citation_count":965,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27301673","id":"PMC_27301673","title":"Regulating Rho GTPases and their regulators.","date":"2016","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27301673","citation_count":671,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11165670","id":"PMC_11165670","title":"Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells.","date":"2001","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11165670","citation_count":652,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18460342","id":"PMC_18460342","title":"Rho GTPases in cancer cell biology.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18460342","citation_count":629,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8524848","id":"PMC_8524848","title":"A role for Rho in Ras transformation.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8524848","citation_count":485,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23176484","id":"PMC_23176484","title":"Rho family GTPases.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/23176484","citation_count":443,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12598902","id":"PMC_12598902","title":"Redox-dependent downregulation of Rho by Rac.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12598902","citation_count":433,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16339495","id":"PMC_16339495","title":"Rho GTPases, statins, and nitric oxide.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16339495","citation_count":393,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15793569","id":"PMC_15793569","title":"Regulation of PTEN by Rho small GTPases.","date":"2005","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15793569","citation_count":393,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12692556","id":"PMC_12692556","title":"The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI.","date":"2003","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12692556","citation_count":382,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11457821","id":"PMC_11457821","title":"Cadherin engagement regulates Rho family GTPases.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11457821","citation_count":364,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10579921","id":"PMC_10579921","title":"Signaling to Rho GTPases.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10579921","citation_count":337,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17666911","id":"PMC_17666911","title":"Rho kinase (ROCK) inhibitors.","date":"2007","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17666911","citation_count":337,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1522900","id":"PMC_1522900","title":"Association between GTPase activators for Rho and Ras families.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1522900","citation_count":310,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16862148","id":"PMC_16862148","title":"FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16862148","citation_count":308,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16243528","id":"PMC_16243528","title":"Cytokinesis: welcome to the Rho zone.","date":"2005","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16243528","citation_count":299,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19204114","id":"PMC_19204114","title":"Wnt signaling pathways meet Rho GTPases.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19204114","citation_count":296,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10047515","id":"PMC_10047515","title":"Effectors for the Rho GTPases.","date":"1999","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10047515","citation_count":282,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12395147","id":"PMC_12395147","title":"Rho/Rho-kinase mediated signaling in physiology and pathophysiology.","date":"2002","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/12395147","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12510192","id":"PMC_12510192","title":"Signalling and crosstalk of Rho GTPases in mediating axon guidance.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12510192","citation_count":250,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18000759","id":"PMC_18000759","title":"Rho GTPases: functions and association with cancer.","date":"2007","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/18000759","citation_count":224,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22984069","id":"PMC_22984069","title":"Initiation of cell wall pattern by a Rho- and microtubule-driven symmetry breaking.","date":"2012","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22984069","citation_count":219,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7871593","id":"PMC_7871593","title":"GAPs for rho-related GTPases.","date":"1994","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/7871593","citation_count":217,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19060892","id":"PMC_19060892","title":"Regulation of cytokinesis by Rho GTPase flux.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19060892","citation_count":214,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9252344","id":"PMC_9252344","title":"Characterization of RAC3, a novel member of the Rho family.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9252344","citation_count":210,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17482681","id":"PMC_17482681","title":"Development of Rho-kinase inhibitors for cardiovascular medicine.","date":"2007","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17482681","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24183240","id":"PMC_24183240","title":"Physiological roles of Rho and Rho effectors in mammals.","date":"2013","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24183240","citation_count":180,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24978113","id":"PMC_24978113","title":"Rho GTPases: masters of cell migration.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24978113","citation_count":172,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16376997","id":"PMC_16376997","title":"Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.","date":"2005","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16376997","citation_count":169,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14999150","id":"PMC_14999150","title":"Rho proteins and cancer.","date":"2004","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/14999150","citation_count":156,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23121917","id":"PMC_23121917","title":"Rho GTPases in platelet function.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/23121917","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25483301","id":"PMC_25483301","title":"Epithelial junctions and Rho family GTPases: the zonular signalosome.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/25483301","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25054920","id":"PMC_25054920","title":"Rho GTPases in collective cell migration.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/25054920","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17850788","id":"PMC_17850788","title":"Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17850788","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17761936","id":"PMC_17761936","title":"Involvement of Rho kinase in endothelial barrier maintenance.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17761936","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28911825","id":"PMC_28911825","title":"Paving the Rho in cancer metastasis: Rho GTPases and beyond.","date":"2017","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28911825","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19965643","id":"PMC_19965643","title":"Rho GTPases in hematopoiesis and hemopathies.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19965643","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31427738","id":"PMC_31427738","title":"Rho GTPases in cancer: friend or foe?","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31427738","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8592759","id":"PMC_8592759","title":"The Rho's progress: a potential role during neuritogenesis for the Rho family of GTPases.","date":"1995","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/8592759","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11389443","id":"PMC_11389443","title":"Regulation of c-myc expression by PDGF through Rho GTPases.","date":"2001","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11389443","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15093731","id":"PMC_15093731","title":"Rho localization in cells and tissues.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15093731","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25941749","id":"PMC_25941749","title":"Regulation of phagocytosis by Rho GTPases.","date":"2015","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/25941749","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28731845","id":"PMC_28731845","title":"Rho Protein: Roles and Mechanisms.","date":"2017","source":"Annual review of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28731845","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9668072","id":"PMC_9668072","title":"Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9668072","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17596509","id":"PMC_17596509","title":"Rho/Rho-associated kinase-II signaling mediates disassembly of epithelial apical junctions.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17596509","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12564953","id":"PMC_12564953","title":"Regulation of endocytic traffic by Rho GTPases.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12564953","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16190977","id":"PMC_16190977","title":"RhoGDIs revisited: novel roles in Rho regulation.","date":"2005","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/16190977","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15981459","id":"PMC_15981459","title":"Regulation of phagocytosis by Rho GTPases.","date":"2005","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15981459","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10692358","id":"PMC_10692358","title":"TraG from RP4 and TraG and VirD4 from Ti plasmids confer relaxosome specificity to the conjugal transfer system of pTiC58.","date":"2000","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/10692358","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20460153","id":"PMC_20460153","title":"Rho kinase and hypertension.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20460153","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10953015","id":"PMC_10953015","title":"Tenascin-C suppresses Rho activation.","date":"2000","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10953015","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27251065","id":"PMC_27251065","title":"Rho Kinases and Cardiac Remodeling.","date":"2016","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/27251065","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16487696","id":"PMC_16487696","title":"Rho GTPases in animal cell mitosis.","date":"2006","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16487696","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16574662","id":"PMC_16574662","title":"Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16574662","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11923206","id":"PMC_11923206","title":"Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11923206","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18442478","id":"PMC_18442478","title":"On the Rho'd: the regulation of membrane protrusions by Rho-GTPases.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18442478","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6252192","id":"PMC_6252192","title":"Physical and functional mapping of RP4-TOL plasmid recombinants: analysis of insertion and deletion mutants.","date":"1980","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6252192","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19162129","id":"PMC_19162129","title":"Rho GTPases in hepatocellular carcinoma.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19162129","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23648569","id":"PMC_23648569","title":"Hijacking of Rho GTPases during bacterial infection.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23648569","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10574699","id":"PMC_10574699","title":"Cell adhesion and Rho small GTPases.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10574699","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8386671","id":"PMC_8386671","title":"GABA rho 2 receptor pharmacological profile: GABA recognition site similarities to rho 1.","date":"1993","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8386671","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8022288","id":"PMC_8022288","title":"Rho and RNA: models for recognition and response.","date":"1994","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8022288","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9529607","id":"PMC_9529607","title":"Regulation of inositol lipid kinases by Rho and Rac.","date":"1998","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/9529607","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24088985","id":"PMC_24088985","title":"Mutationally activated Rho GTPases in cancer.","date":"2013","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24088985","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15146061","id":"PMC_15146061","title":"Rho kinase regulates the intracellular micromechanical response of adherent cells to rho activation.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15146061","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12372594","id":"PMC_12372594","title":"B plexins activate Rho through PDZ-RhoGEF.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12372594","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24042317","id":"PMC_24042317","title":"Rho/Rho-associated kinase pathway in glaucoma (Review).","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24042317","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10491334","id":"PMC_10491334","title":"Distribution of Rho-kinase in the bovine brain.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10491334","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15981462","id":"PMC_15981462","title":"Clostridial Rho-inhibiting protein toxins.","date":"2005","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15981462","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17115030","id":"PMC_17115030","title":"The armadillo protein p0071 regulates Rho signalling during cytokinesis.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17115030","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32392742","id":"PMC_32392742","title":"Dysregulation of Rho GTPases in Human Cancers.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32392742","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18298893","id":"PMC_18298893","title":"Rho GTPases of the RhoBTB subfamily and tumorigenesis.","date":"2008","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/18298893","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9823474","id":"PMC_9823474","title":"The Rho GTPases in macrophage motility and chemotaxis.","date":"1998","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/9823474","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18417612","id":"PMC_18417612","title":"The Rho GDI Rdi1 regulates Rho GTPases by distinct mechanisms.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18417612","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17764949","id":"PMC_17764949","title":"Actin and Rho GTPases in herpesvirus biology.","date":"2007","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17764949","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29531464","id":"PMC_29531464","title":"Long noncoding RNA RP4 functions as a competing endogenous RNA through miR-7-5p sponge activity in colorectal cancer.","date":"2018","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/29531464","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24691223","id":"PMC_24691223","title":"Rho GTPases at the crossroad of signaling networks in mammals: impact of Rho-GTPases on microtubule organization and dynamics.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24691223","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16014623","id":"PMC_16014623","title":"RA-RhoGAP, Rap-activated Rho GTPase-activating protein implicated in neurite outgrowth through Rho.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16014623","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16900393","id":"PMC_16900393","title":"Multifaceted role of Rho proteins in angiogenesis.","date":"2005","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/16900393","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16441511","id":"PMC_16441511","title":"Neuronal responses to myelin are mediated by rho kinase.","date":"2006","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16441511","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17599352","id":"PMC_17599352","title":"Transcription termination defective mutants of Rho: role of different functions of Rho in releasing RNA from the elongation complex.","date":"2007","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17599352","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20876660","id":"PMC_20876660","title":"Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20876660","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19115379","id":"PMC_19115379","title":"Lysophosphatidylcholine induces glial cell activation: role of rho kinase.","date":"2009","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/19115379","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24375503","id":"PMC_24375503","title":"Rho GTPases and cancer.","date":"2013","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24375503","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24691164","id":"PMC_24691164","title":"Rho'ing in and out of cells: viral interactions with Rho GTPase signaling.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24691164","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27807006","id":"PMC_27807006","title":"RHO binding to FAM65A regulates Golgi reorientation during cell migration.","date":"2016","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/27807006","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22975682","id":"PMC_22975682","title":"Regulation of autophagosome formation by Rho kinase.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/22975682","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6450749","id":"PMC_6450749","title":"Introduction of bacteriophage Mu into bacteria of various genera and intergeneric gene transfer by RP4::Mu.","date":"1981","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6450749","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25483305","id":"PMC_25483305","title":"Rho GTPases in embryonic development.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/25483305","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15791595","id":"PMC_15791595","title":"Rho mediates cytokinesis and epiboly via ROCK in zebrafish.","date":"2005","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/15791595","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26768244","id":"PMC_26768244","title":"Rho Kinases in Autoimmune Diseases.","date":"2016","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26768244","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22144264","id":"PMC_22144264","title":"Historical overview of Rho GTPases.","date":"2012","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22144264","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21792909","id":"PMC_21792909","title":"Functional role of Rho-kinase in ameloblast differentiation.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21792909","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10816250","id":"PMC_10816250","title":"Citron, a Rho target that affects contractility during cytokinesis.","date":"2000","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/10816250","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15226371","id":"PMC_15226371","title":"Disruption of Rho signal transduction upon cell detachment.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15226371","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16822336","id":"PMC_16822336","title":"Localization of the Rho GTPases and some Rho effector proteins in the sperm of several mammalian species.","date":"2006","source":"Zygote (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16822336","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21686121","id":"PMC_21686121","title":"RhoGDI: A rheostat for the Rho switch.","date":"2010","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/21686121","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20726051","id":"PMC_20726051","title":"RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it.","date":"2010","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/20726051","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2137202","id":"PMC_2137202","title":"A point mutation of the rhodopsin gene in one form of retinitis pigmentosa.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2137202","citation_count":885,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11076863","id":"PMC_11076863","title":"DNA cloning using in vitro site-specific recombination.","date":"2000","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/11076863","citation_count":815,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26200343","id":"PMC_26200343","title":"Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26200343","citation_count":611,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6589631","id":"PMC_6589631","title":"Isolation and nucleotide sequence of the gene encoding human rhodopsin.","date":"1984","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6589631","citation_count":491,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1356370","id":"PMC_1356370","title":"Constitutively active mutants of rhodopsin.","date":"1992","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/1356370","citation_count":434,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1418997","id":"PMC_1418997","title":"Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa.","date":"1992","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/1418997","citation_count":416,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2215617","id":"PMC_2215617","title":"Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa.","date":"1990","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2215617","citation_count":398,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1862076","id":"PMC_1862076","title":"Rhodopsin mutations in autosomal dominant retinitis pigmentosa.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1862076","citation_count":396,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28753425","id":"PMC_28753425","title":"Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28753425","citation_count":359,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3350146","id":"PMC_3350146","title":"Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitylated.","date":"1988","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/3350146","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2218504","id":"PMC_2218504","title":"Rhodopsin mutants that bind but fail to activate transducin.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2218504","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15823756","id":"PMC_15823756","title":"Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy.","date":"2005","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15823756","citation_count":316,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8107847","id":"PMC_8107847","title":"Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8107847","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12601165","id":"PMC_12601165","title":"Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12601165","citation_count":309,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1833777","id":"PMC_1833777","title":"Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1833777","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19836958","id":"PMC_19836958","title":"A G protein-coupled receptor at work: the rhodopsin model.","date":"2009","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19836958","citation_count":299,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7523628","id":"PMC_7523628","title":"A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment.","date":"1994","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7523628","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11256614","id":"PMC_11256614","title":"Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.","date":"2000","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11256614","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12091393","id":"PMC_12091393","title":"A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12091393","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8253795","id":"PMC_8253795","title":"Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8253795","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6140680","id":"PMC_6140680","title":"Human visual pigments: microspectrophotometric results from the eyes of seven persons.","date":"1983","source":"Proceedings of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6140680","citation_count":248,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8358437","id":"PMC_8358437","title":"Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness.","date":"1993","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8358437","citation_count":248,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8943080","id":"PMC_8943080","title":"Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8943080","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29899450","id":"PMC_29899450","title":"Cryo-EM structure of human rhodopsin bound to an inhibitory G protein.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29899450","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25203160","id":"PMC_25203160","title":"Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25203160","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2613244","id":"PMC_2613244","title":"Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2613244","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35651,"output_tokens":5816,"usd":0.097097},"stage2":{"model":"claude-opus-4-6","input_tokens":9450,"output_tokens":4235,"usd":0.229687},"total_usd":0.636174,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":46580,"output_tokens":5486,"usd":0.111015},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8715,"output_tokens":3547,"usd":0.198375}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Rho GTPases act as molecular switches that cycle between GTP-bound active and GDP-bound inactive conformations; GTP binding induces a conformational change that promotes interaction with effector proteins to generate cellular responses including actin cytoskeleton regulation, cell polarity, microtubule dynamics, membrane transport, and transcription factor activity.\",\n      \"method\": \"Review synthesizing biochemical and cell biological studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — foundational mechanistic framework replicated across many labs, >3900 citations\",\n      \"pmids\": [\"12478284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Rho GTPase (specifically RhoA) induces assembly of contractile actin-based stress fibers, while also regulating focal adhesion formation; dominant-negative N19-RhoA inhibits Ras-induced focus formation and reverts Ras transformation, placing RhoA downstream of oncogenic Ras in transformation signaling.\",\n      \"method\": \"Dominant-negative and constitutively active mutant expression in fibroblasts; focus-formation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with dominant-negative/constitutively active mutants, replicated across multiple cell lines, >485 citations\",\n      \"pmids\": [\"8524848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rac-mediated ROS production leads to downregulation of RhoA activity through inhibition of LMW-PTP, which increases tyrosine phosphorylation and activation of p190RhoGAP, thus coupling cellular redox state to actin cytoskeleton control via Rho inactivation.\",\n      \"method\": \"Co-immunoprecipitation, ROS measurement, phosphatase activity assays, dominant-negative/constitutively active mutants, cell spreading assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single study establishing a mechanistic pathway from ROS to p190RhoGAP to RhoA inactivation\",\n      \"pmids\": [\"12598902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The neurotrophin receptor p75NTR directly interacts with Rho-GDI, facilitating release of prenylated RhoA from Rho-GDI and thereby activating RhoA; MAG and Nogo strengthen the p75NTR–RhoGDI interaction, explaining myelin-mediated RhoA activation and inhibition of axon growth.\",\n      \"method\": \"Direct binding assays (co-immunoprecipitation, pulldown), peptide inhibition, functional neurite outgrowth assays\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and pulldown establishing direct p75NTR–RhoGDI interaction plus functional consequence, replicated with peptide inhibitor\",\n      \"pmids\": [\"12692556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Cadherin engagement directly inhibits RhoA activity while stimulating Rac1 activity; deletion of the cadherin cytoplasmic domain abolishes these effects, indicating that cadherin-mediated adhesion regulates RhoA through the cytoplasmic domain.\",\n      \"method\": \"Rho-GTP pull-down activity assays, calcium switch experiments, cadherin-coated substrate binding, function-blocking antibodies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays (GTP pulldown, antibody blocking, domain deletion) showing cadherin cytoplasmic domain requirement for RhoA suppression\",\n      \"pmids\": [\"11457821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RhoA and Cdc42 regulate the intracellular localization of PTEN in leukocytes; active RhoA stimulates PTEN phospholipid phosphatase activity via its downstream effector ROCK, and specific PTEN residues are required for this regulation, which in turn controls chemotaxis.\",\n      \"method\": \"Co-immunoprecipitation, PTEN phosphatase activity assays, mutagenesis of PTEN residues, ROCK inhibition, chemotaxis assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro phosphatase assay, mutagenesis, functional chemotaxis readout with multiple orthogonal methods\",\n      \"pmids\": [\"15793569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"p190, a binding partner of Ras-GAP in growth-factor-stimulated cells, functions as a GAP specifically for Rho family GTPases (not Ras or Rab); this links Ras and Rho signaling pathways through the Ras-GAP/p190 complex.\",\n      \"method\": \"Biochemical GAP activity assay with recombinant p190, co-immunoprecipitation of Ras-GAP/p190 complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro GAP activity reconstitution plus co-IP; >310 citations, foundational study\",\n      \"pmids\": [\"1522900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FilGAP, a filamin A-binding RacGAP, is phosphorylated by ROCK (a Rho effector), which stimulates its RacGAP activity; this defines a RhoA→ROCK→FilGAP→Rac inactivation cascade that suppresses leading-edge protrusion and promotes cell retraction and polarity.\",\n      \"method\": \"In vitro ROCK kinase assay, siRNA knockdown, dominant-negative constructs, cell spreading assays, ROCK inhibitor Y-27632\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase phosphorylation assay plus siRNA knockdown and functional bleb/lamellae assays\",\n      \"pmids\": [\"16862148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RhoA drives actomyosin contractility during cytokinesis through local accumulation of GTP-bound active RhoA at the cell equator, where it promotes contractile ring assembly; active RhoA is spatially restricted to a discrete zone at the correct time and place.\",\n      \"method\": \"Active RhoA biosensors (FRET/GST-RBD pulldown), live-cell imaging, dominant-negative/constitutively active mutants\",\n      \"journal\": \"Trends in cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — active RhoA detection at equatorial zone by biosensor imaging and pulldown, replicated across labs\",\n      \"pmids\": [\"16243528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MgcRacGAP GAP activity is required early during cytokinesis to focus and maintain the RhoA activity zone; loss of GAP activity leads to unfocused or oscillating RhoA zones, demonstrating that constant GTP hydrolysis flux through the GTPase cycle is necessary for proper cytokinesis.\",\n      \"method\": \"Point mutation of GAP domain, live-cell RhoA activity biosensor imaging in Xenopus embryos\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — structure-guided mutagenesis of catalytic residue combined with live RhoA biosensor, replicated in an ortholog\",\n      \"pmids\": [\"19060892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Distinct regions of RhoA (amino acids 23-40 and 75-92) selectively bind different classes of Rho effectors: aa 23-40 is required for citron binding, aa 75-92 for rhophilin binding, while either region can bind ROCK-I/ROCK-II; both regions independently induce stress fibers in a ROCK-dependent manner.\",\n      \"method\": \"Yeast two-hybrid with RhoA/Rac chimeras, ligand overlay assay with recombinant ROCK, transfection of HeLa cells, Y-27632 ROCK inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — chimeric protein mapping combined with in vitro ligand overlay assay and functional cell-based readout\",\n      \"pmids\": [\"9668072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Rho-kinase (ROCK), acting downstream of Rho, regulates smooth muscle Ca2+ sensitization and contraction by inhibiting myosin phosphatase, thereby maintaining elevated myosin light chain phosphorylation in a Ca2+-independent manner; the same pathway drives stress-fiber formation and cytokinesis in non-muscle cells.\",\n      \"method\": \"Pharmacological inhibition (Y-27632), kinase activity assays, myosin phosphatase activity assays, smooth muscle contraction measurements\",\n      \"journal\": \"Trends in pharmacological sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase and phosphatase assays replicated across multiple labs; >652 citations\",\n      \"pmids\": [\"11165670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The PDZ domain of B plexin receptors directly binds PDZ-RhoGEF; clustering of plexin-B1 activates RhoA through PDZ-RhoGEF, leading to stress fiber formation; mutation of the carboxy-terminal plexin-B1 residues or expression of dominant-negative PDZ-RhoGEF abolishes this activation.\",\n      \"method\": \"Yeast two-hybrid, dominant-negative PDZ-RhoGEF expression, stress fiber formation assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — yeast two-hybrid plus dominant-negative functional assay; single lab\",\n      \"pmids\": [\"12372594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Rap1 activates RA-RhoGAP (a Rho-specific GAP containing a Ras-association domain) by direct binding to its RA domain, which stimulates RA-RhoGAP GAP activity toward RhoA, leading to RhoA inactivation and promotion of neurite outgrowth; knockdown of RA-RhoGAP reduces Rap1-induced neurite outgrowth.\",\n      \"method\": \"In vitro GAP activity assay, pulldown with GTP-Rap1, siRNA knockdown, neurite outgrowth assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro GAP assay plus siRNA knockdown with functional neurite outgrowth readout\",\n      \"pmids\": [\"16014623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GEF-H1/RhoA/ROCK-II signaling pathway drives disassembly of the apical junctional complex; calcium depletion activates RhoA and causes GEF-H1 translocation to contractile F-actin rings; siRNA knockdown of ROCK-II (not ROCK-I) or GEF-H1 prevents AJC disassembly.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition, immunofluorescence, RhoA activity pulldown assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific siRNA isoform knockdown of ROCK-II vs. ROCK-I combined with RhoA activity assay and GEF-H1 localization\",\n      \"pmids\": [\"17596509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The armadillo protein p0071 localizes to the midbody during cytokinesis and regulates local RhoA activity through direct association with RhoA and physical/functional interaction with the RhoGEF Ect2; knockdown or overexpression of p0071 causes cytokinesis failure with multinucleation.\",\n      \"method\": \"siRNA knockdown, overexpression, co-immunoprecipitation of p0071 with RhoA and Ect2, immunofluorescence\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP establishing RhoA and Ect2 binding plus functional cytokinesis phenotype via knockdown\",\n      \"pmids\": [\"17115030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Citron, a RhoA effector containing a Ser/Thr kinase domain related to ROCK, localizes to the cleavage furrow and midbody during cytokinesis; overexpression of C-terminally truncated Citron causes abnormal contractions specifically during cytokinesis, producing multinucleated cells, establishing Citron as a Rho effector modulating cytokinetic contractility.\",\n      \"method\": \"Immunolocalization, overexpression of truncation mutants, multinucleation assay\",\n      \"journal\": \"Microscopy research and technique\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — localization plus dominant-negative truncation phenotype; single lab\",\n      \"pmids\": [\"10816250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Tenascin-C suppresses RhoA activation in cells on fibronectin-containing fibrin matrices, eliminating stress fibers; enforced constitutive RhoA activation circumvents tenascin-C effects, and C3 transferase reversal confirms RhoA specificity; this defines an ECM-level switch regulating cytoskeletal organization via Rho.\",\n      \"method\": \"Rho-GTP pulldown assay, C3 transferase treatment, constitutively active RhoA overexpression, actin staining\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — GTP-pulldown activity assay plus gain-of-function rescue and C3 inhibition in same system\",\n      \"pmids\": [\"10953015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RhoA is localized at lateral membranes in epithelial cells and concentrated at the cleavage furrow during cytokinesis; in A431 cells, EGF stimulation causes RhoA translocation from cytoplasm to elongating microvilli within 30 seconds; Myc/GFP-tagged RhoA does not always reflect endogenous localization, indicating tag artifacts.\",\n      \"method\": \"Immunofluorescence with evaluated anti-Rho antibodies, subcellular fractionation, EGF stimulation, multiple fixation protocols\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization of endogenous protein with careful antibody validation and multiple fixation protocols\",\n      \"pmids\": [\"15093731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Active RHOA, RHOB, and RHOC bind to FAM65A, a new Rho effector, which links Rho proteins to CCM3 and its interacting kinases MST3 and MST4 at the Golgi; RHO binding to FAM65A causes MST3/MST4 relocation from the Golgi in a CCM3-dependent manner, driving Golgi reorientation toward the leading edge and directional cell migration.\",\n      \"method\": \"Co-immunoprecipitation/pulldown of FAM65A with active Rho proteins, siRNA knockdown, live-cell Golgi orientation assay, MST kinase activity assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP establishing RHO–FAM65A–CCM3–MST3/4 complex, kinase activity assay, and functional directional migration readout\",\n      \"pmids\": [\"27807006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cell adhesion is required for serum-stimulated Rho→Rho-kinase signal transduction leading to MLC di-phosphorylation (Thr18/Ser19); cell detachment impairs Rho-kinase-mediated MLC phosphorylation without inhibiting RhoA itself, and reattachment to fibronectin (not poly-L-lysine) restores the response, demonstrating integrin-fibronectin-dependent permissiveness for Rho-kinase substrate phosphorylation.\",\n      \"method\": \"Phospho-specific antibodies for MLC and MYPT1, constitutively active RhoA and Rho-kinase expression, cell detachment/reattachment assays on different substrates\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — phospho-specific antibodies combined with constitutively active constructs and substrate comparison establish mechanistic requirement for integrin engagement\",\n      \"pmids\": [\"15226371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RhoA mediates chemorepulsion and growth cone turning in Xenopus spinal neurons in response to lysophosphatidic acid; dominant-negative RhoA abolishes LPA-induced repulsion, and asymmetric Rho kinase activity across the growth cone is sufficient to trigger turning; crosstalk exists between Cdc42 and RhoA pathways through myosin activity.\",\n      \"method\": \"Dominant-negative/constitutively active GTPase expression in Xenopus neurons, gradient of LPA, ROCK inhibitor, live-cell growth cone turning assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative epistasis plus pharmacological ROCK inhibition and functional turning assay in primary neurons\",\n      \"pmids\": [\"12510192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In zebrafish embryos, Rho (specifically RhoA) mediates cytokinesis via cleavage furrow protein assembly and actomyosin ring constriction, and also drives epiboly and gastrulation cell movements; C3-exoenzyme inhibition is rescued by constitutively active RhoA; ROCK inhibitor Y-27632 phenocopies C3 treatment, placing ROCK downstream of Rho in both processes.\",\n      \"method\": \"Microinjection of C3 exoenzyme, constitutively active RhoA rescue, ROCK inhibitor Y-27632, β-catenin and actin immunostaining in zebrafish embryos\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — C3 inhibition with constitutively active rescue and pharmacological ROCK inhibition in an ortholog developmental model\",\n      \"pmids\": [\"15791595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cardiac-specific inhibition of Rho GTPases (RhoA, Rac1, Cdc42) by transgenic expression of RhoGDIα disrupts cardiac morphogenesis (incomplete looping, lack of trabeculation), inhibits cardiomyocyte proliferation, upregulates p21 and downregulates cyclin A, demonstrating essential roles of Rho GTPases in cardiac cell cycle progression.\",\n      \"method\": \"Transgenic mouse cardiac-specific RhoGDIα overexpression, RhoA/Rac1/Cdc42 activity assays (membrane translocation), anti-phosphohistone H3 staining, p21/cyclin A immunostaining\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo genetic loss-of-function with multiple molecular readouts (GTPase activity, proliferation markers, cell-cycle proteins)\",\n      \"pmids\": [\"11923206\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RhoA (and the broader Rho GTPase family) functions as a GDP/GTP molecular switch that, upon GTP loading induced by GEFs (e.g., Ect2, GEF-H1, PDZ-RhoGEF), undergoes a conformational change enabling binding to structurally distinct effectors (ROCK1/2, citron, PKN/rhophilin, mDia, FAM65A) through two separable binding surfaces (aa 23–40 and 75–92); active RhoA drives actomyosin contractility primarily through ROCK-mediated inhibition of myosin phosphatase and direct MLC phosphorylation, controls cytokinetic ring assembly at the equatorial zone via coordinated Ect2/MgcRacGAP GEF–GAP flux, regulates Golgi polarity through FAM65A–CCM3–MST kinases, and is spatially and temporally controlled by RhoGDI-mediated membrane extraction, p190RhoGAP (activated downstream of Rac-ROS), p75NTR-mediated GDI displacement, and cadherin/integrin-dependent inputs from the extracellular matrix.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI need to classify each paper carefully. The gene query is \"RHO\" but there are clearly two different genes represented:\n\n1. **RHO** = Rhodopsin (the visual pigment GPCR gene on chromosome 3) - from the gene2pubmed-curated papers\n2. **RHO GTPases** (RhoA, RhoB, RhoC family) - from the retrieved corpus papers [1]-[100]\n\nAdditionally, some retrieved papers contain:\n- Papers about bacterial Rho transcription termination factor (EXCLUDE - symbol collision, prokaryotic)\n- Papers about plant ROP/RHO GTPases (EXCLUDE - symbol collision, plants)\n- Papers about lncRNA RP4 (EXCLUDE - alt-locus product)\n- Papers about RP4 plasmid (EXCLUDE - symbol collision)\n- Papers about GABA rho receptors (EXCLUDE - different gene)\n\nThe gene2pubmed-curated papers are clearly about **rhodopsin (RHO)** - the human visual pigment GPCR. These are the canonical RHO gene papers.\n\nThe retrieved corpus papers [1]-[100] are largely about **Rho GTPases** (RhoA/B/C family), which are a completely different gene family. The HGNC symbol \"RHO\" refers to rhodopsin, not RhoA GTPase. The Rho GTPase papers represent an alias collision.\n\nI will KEEP the gene2pubmed-curated papers about rhodopsin and EXCLUDE the Rho GTPase papers.\n\nAdditional exclusions from retrieved papers:\n- [45] - bacterial Rho transcription termination factor - EXCLUDE\n- [51] - RP4 plasmid - EXCLUDE  \n- [59] - TOL/RP4 plasmid - EXCLUDE\n- [63] - GABA rho2 receptor - EXCLUDE (different gene)\n- [64] - E. coli Rho factor - EXCLUDE\n- [78] - lncRNA RP4 - EXCLUDE\n- [83] - E. coli Rho transcription terminator - EXCLUDE\n- [90] - RP4 bacteriophage - EXCLUDE\n- [24] - Plant ROP11 - EXCLUDE (plant symbol collision)\n\nAll other retrieved papers [1]-[100] (Rho GTPase family) - these are about RhoA/Rac/Cdc42 GTPases, not the RHO gene (rhodopsin). EXCLUDE as alias collision.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"The human rhodopsin gene was isolated and fully sequenced, revealing a coding region interrupted by four introns at positions analogous to bovine rhodopsin, and a deduced amino acid sequence of 348 residues that is 93.4% homologous to bovine rhodopsin.\",\n      \"method\": \"Gene isolation and nucleotide sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing of isolated gene, foundational structural characterization\",\n      \"pmids\": [\"6589631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Two adjacent cysteine residues (Cys-322 and Cys-323) in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated, identifying a post-translational lipid modification site on the protein.\",\n      \"method\": \"Covalent coupling to CPG-thiol glass, CNBr peptide separation and chemical characterization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical identification of palmitoylation sites by peptide fractionation\",\n      \"pmids\": [\"3350146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"A C→A transversion in codon 23 of the rhodopsin gene (Pro23His substitution) was identified as a mutation causing one form of autosomal dominant retinitis pigmentosa, establishing RHO as the disease gene.\",\n      \"method\": \"PCR-based mutation screening in patients vs. controls\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation identified in 17/148 unrelated patients, absent in 102 controls, correlated with conserved residue across opsins\",\n      \"pmids\": [\"2137202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Three additional rhodopsin mutations (two in codon 347, one in codon 58) were found to cause autosomal dominant retinitis pigmentosa, and together with Pro23His account for ~18% of ADRP cases, with all patients showing abnormal rod function on ERG.\",\n      \"method\": \"Mutation screening of rhodopsin gene exons in 150 unrelated ADRP patients\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutations identified and correlated with disease phenotype across large patient cohort\",\n      \"pmids\": [\"2215617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Mutations in the second and third cytoplasmic loops of rhodopsin (CD2 and EF1 mutants) allow normal transducin (Gt) binding but prevent Gt release in the presence of GTP, while a mutation at the cytoplasmic border of TM3 (CD1) prevents Gt binding entirely, demonstrating that distinct cytoplasmic loop regions are required for Gt activation vs. binding.\",\n      \"method\": \"Site-directed mutagenesis, flash photolysis to monitor Gt binding and dissociation, GTPase activity assay\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis with direct functional assays for G protein binding and activation\",\n      \"pmids\": [\"2218504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Systematic screening identified 13 different point mutations at 12 amino acid positions in the rhodopsin gene among 161 ADRP patients, with mutation presence/absence correlating with disease status in 174/179 individuals tested in 17 families.\",\n      \"method\": \"PCR and denaturing gradient gel electrophoresis screening\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large-scale family cosegregation analysis across multiple independent pedigrees\",\n      \"pmids\": [\"1862076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A comprehensive survey of all rhodopsin gene exons in 150 ADRP patients identified 17 different mutations (all single amino acid substitutions), with class II mutations clustering in transmembrane and extracellular domains, establishing a mutational spectrum and preliminary structure-function map.\",\n      \"method\": \"Complete exon sequencing of rhodopsin gene in ADRP patients\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive mutational survey with cosegregation analysis\",\n      \"pmids\": [\"1833777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Mutation of Lys-296 (retinal attachment site) or Glu-113 (Schiff base counterion) in rhodopsin causes constitutive activation of opsin (transducin activation in the absence of chromophore and light), establishing that a salt bridge between these two residues constrains rhodopsin to an inactive conformation.\",\n      \"method\": \"Site-directed mutagenesis, transducin activation assay in vitro\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assay with mutagenesis defining catalytic mechanism; K296E also found in RP patients\",\n      \"pmids\": [\"1356370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Transgenic mice expressing the human P23H rhodopsin mutation develop photoreceptor degeneration in all three lines, with severity correlated with transgene expression level, establishing the pathogenicity of this mutation in vivo; overexpression of wild-type human rod opsin also causes degeneration.\",\n      \"method\": \"Transgenic mouse generation, histology, ERG, immunostaining\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple transgenic lines with dose-dependent phenotype and functional validation by ERG\",\n      \"pmids\": [\"1418997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Biochemical analysis of 21 ADRP rhodopsin mutants revealed two classes: class I mutants (G51V, V345M, P347S) resemble wild-type in yield, retinal regenerability, and plasma membrane localization; class II mutants are reduced in yield, fail to regenerate with 11-cis-retinal, and accumulate in the endoplasmic reticulum, with class II amino acids located in transmembrane and extracellular domains.\",\n      \"method\": \"Site-directed mutagenesis, transfection of HEK293S cells, immunofluorescence, retinal regeneration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — systematic mutagenesis with multiple biochemical readouts defining two mechanistic classes\",\n      \"pmids\": [\"8253795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The GABA rho2 receptor was characterized, showing that it forms homooligomeric GABA-gated channels when expressed in Xenopus oocytes with pharmacological profiles similar to rho1 but with slower responses and higher potency for most agonists; this gene is distinct from the rhodopsin RHO gene.\",\n      \"method\": \"Xenopus oocyte expression, electrophysiology\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"EXCLUDED — GABA rho2 is a different gene, not rhodopsin RHO\",\n      \"pmids\": [\"8386671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The Ala292Glu rhodopsin mutation causes congenital stationary night blindness by anomalously activating transducin in the absence of chromophore (constitutive activation), while retaining normal light-dependent transducin activation, defining a mechanism for night blindness distinct from RP mutations.\",\n      \"method\": \"In vitro transducin activation assay with recombinant mutant opsin\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution assay directly measuring transducin activation with and without chromophore\",\n      \"pmids\": [\"8358437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The G90D rhodopsin mutation causes congenital night blindness by constitutively activating opsin; Asp-90 can substitute for the Schiff base counterion Glu-113, demonstrating proximity of these residues in 3D structure and a common mechanism for constitutively activating mutations that disrupt the Lys296–Glu113 salt bridge.\",\n      \"method\": \"Site-directed mutagenesis, transducin activation assay, suppressor mutation analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and suppressor analysis revealing molecular mechanism\",\n      \"pmids\": [\"8107847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A rhodopsin carboxy-terminus truncation mutation (Q344ter) does not impair transducin activation or rhodopsin kinase phosphorylation in vitro, but causes mislocalization of mutant protein to the plasma membrane of photoreceptor cell bodies in transgenic mice rather than outer segments, establishing that the C-terminus contains a signal required for outer segment targeting.\",\n      \"method\": \"Site-directed mutagenesis, transducin activation assay, transgenic mice, immunofluorescence confocal microscopy, electrophysiology\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro functional assays plus in vivo transgenic localization studies with multiple methods\",\n      \"pmids\": [\"7523628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Transgenic mice expressing the P347S rhodopsin mutation show photoreceptor degeneration correlated with transgene expression, with accumulation of rhodopsin-laden extracellular vesicles near the inner/outer segment junction, indicating defective vectorial transport of rhodopsin to outer segment disc membranes as the pathogenic mechanism.\",\n      \"method\": \"Transgenic mice, ERG, immunocytochemistry, confocal microscopy, ultrastructural immunocytochemistry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple lines with graded expression, ultrastructural and immunocytochemical localization\",\n      \"pmids\": [\"8943080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The P23H rhodopsin mutation causes the protein to form high-molecular-weight oligomeric aggregates and accumulate in aggresomes (pericentriolar inclusion bodies requiring intact microtubules) in transfected cells; the aggregated protein is targeted for degradation by the ubiquitin-proteasome system, and its expression impairs overall proteasome function.\",\n      \"method\": \"Transfection, FRET, immunofluorescence, proteasome inhibitor treatment, dominant-negative ubiquitin co-expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including FRET for aggregation detection, functional proteasome impairment assay\",\n      \"pmids\": [\"12091393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The conserved NPxxY(x)5,6F motif in rhodopsin TM7 connects to cytoplasmic helix 8; the interaction between Y306 and F313 within this motif must be disrupted during Meta I/Meta II transition, as mutations eliminating this interaction rescue Meta II formation in 9-demethyl-retinal-reconstituted rhodopsin. However, these mutations dramatically reduce G protein activation, indicating helix 8 realignment is separately required for proper signal transduction.\",\n      \"method\": \"Site-directed mutagenesis (Ala replacements, disulfide bond engineering), UV-vis spectroscopy, transducin activation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus disulfide trapping with multiple functional readouts\",\n      \"pmids\": [\"12601165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Rhodopsin mutations causing ADRP can be classified into biochemical groups based on protein folding, retinal binding, membrane localization, and post-translational processing, with distinct gain-of-function (constitutive activation, dominant-negative) mechanisms underlying different mutations.\",\n      \"method\": \"Systematic review and classification of published biochemical and cellular studies\",\n      \"journal\": \"Trends in molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — synthesis of prior experimental data; no new primary experiments\",\n      \"pmids\": [\"15823756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Activation of rhodopsin is mediated by photoisomerization of retinal triggering stepwise rearrangement of TM5-TM6 that opens a cytoplasmic crevice; the C-terminus of the Gα subunit of transducin binds into this crevice, and the Gα C-terminal helix acts as a transmission rod to the nucleotide binding site to catalyze GDP/GTP exchange.\",\n      \"method\": \"Integration of biochemical studies with high-resolution 3D crystal structures\",\n      \"journal\": \"Trends in biochemical sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural and biochemical synthesis defining G protein activation mechanism\",\n      \"pmids\": [\"19836958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Molecular dynamics simulations of rhodopsin (and other GPCRs) reveal that a hydrophobic layer near the NPxxY motif acts as a gate that opens to form a continuous internal water channel only upon receptor activation; the conserved Y7.53 undergoes transitions between three conformations representing inactive, G-protein-activated, and metastates.\",\n      \"method\": \"Molecular dynamics simulation validated against available crystal structures\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 4 — computational simulation, consistent with structural data but not directly experimentally validated\",\n      \"pmids\": [\"25203160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of constitutively active human rhodopsin bound to pre-activated mouse visual arrestin (determined by serial femtosecond X-ray laser crystallography) reveals that rhodopsin uses TM7 and helix 8 to recruit arrestin, and arrestin adopts a ~20° inter-domain rotation that opens a cleft to accommodate a short helix from the second intracellular loop of rhodopsin.\",\n      \"method\": \"Serial femtosecond X-ray laser (XFEL) crystallography, biochemical mutagenesis validation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with extensive biochemical and mutagenesis validation\",\n      \"pmids\": [\"26200343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"XFEL crystal structure of the rhodopsin-arrestin complex shows that phosphorylated C-terminal tail residues T336 and S338 of rhodopsin, together with E341, form an intermolecular β-sheet with N-terminal β-strands of arrestin through electrostatic interactions with three positively charged pockets, defining a phosphorylation code for arrestin recruitment common to multiple GPCRs.\",\n      \"method\": \"X-ray free electron laser (XFEL) crystallography, phosphorylation site identification, mutagenesis and validation across multiple GPCRs\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution structure with mutagenesis and cross-GPCR validation\",\n      \"pmids\": [\"28753425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cryo-EM structure of activated human rhodopsin bound to inhibitory Gi protein reveals that major interactions are mediated by the C-terminal helix of the Giα subunit wedged into the cytoplasmic cavity of the TM helix bundle and contacting the N-terminus of helix 8 of rhodopsin; structural comparison with Gs-bound β2AR and arrestin-bound rhodopsin identifies unique structural signatures distinguishing Gs, Gi, and arrestin coupling.\",\n      \"method\": \"Cryo-electron microscopy structure determination, structural comparison\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with comparative structural analysis across multiple GPCR signaling complexes\",\n      \"pmids\": [\"29899450\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Rhodopsin (RHO) is a light-sensitive GPCR in rod photoreceptors that is constrained in an inactive conformation by a Lys296–Glu113 salt bridge; photoisomerization of 11-cis-retinal disrupts this salt bridge and triggers stepwise TM5–TM6 rearrangement that opens a cytoplasmic crevice to catalyze GDP/GTP exchange in transducin (Gαt), with phosphorylation of C-terminal residues T336/S338 by rhodopsin kinase then recruiting arrestin via an intermolecular β-sheet interaction that terminates G protein signaling; mutations in its transmembrane and extracellular domains cause misfolding and ER retention (class II ADRP), while C-terminal mutations disrupt outer segment targeting, and certain mutations constitutively activate the receptor to cause night blindness.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RhoA is a GDP/GTP molecular switch that drives actomyosin contractility, stress fiber formation, cytokinesis, cell polarity, and directed migration by cycling between GTP-bound active and GDP-bound inactive states under the control of upstream GEFs, GAPs, and GDI proteins [PMID:12478284, PMID:8524848]. GTP-loaded RhoA engages structurally distinct effectors—ROCK, citron, and FAM65A—through two separable binding surfaces (aa 23–40 and 75–92), with ROCK driving myosin light chain phosphorylation via myosin phosphatase inhibition to generate contractile force during cytokinesis, smooth muscle contraction, and cell retraction [PMID:9668072, PMID:11165670, PMID:16243528]. RhoA activity is spatially focused at the cytokinetic equator by Ect2-mediated GTP loading and MgcRacGAP-mediated GTP hydrolysis flux, and is tuned by extracellular inputs including cadherin engagement, integrin–fibronectin adhesion, p75NTR-mediated RhoGDI displacement, and Rac-ROS–p190RhoGAP–dependent inactivation [PMID:19060892, PMID:17115030, PMID:11457821, PMID:12598902, PMID:12692556]. Beyond contractility, RhoA signals through the FAM65A–CCM3–MST3/4 axis to reorient the Golgi for directional migration, through ROCK–FilGAP to suppress Rac-driven protrusion, and through ROCK-dependent PTEN activation to regulate chemotaxis [PMID:27807006, PMID:16862148, PMID:15793569].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of p190 as a Rho-specific GAP that complexes with Ras-GAP established the first molecular link between Ras and Rho signaling cascades, revealing that RhoA activity is negatively regulated by a dedicated GAP.\",\n      \"evidence\": \"In vitro GAP activity reconstitution with recombinant p190 and co-immunoprecipitation of the Ras-GAP/p190 complex\",\n      \"pmids\": [\"1522900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of upstream signals activating p190 was unknown\", \"Whether p190 preferentially targets RhoA vs. Rac1/Cdc42 in vivo was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Chimeric RhoA/Rac mapping revealed two separable effector-binding surfaces (aa 23–40 and 75–92) with differential selectivity for citron, rhophilin, and ROCK, establishing that RhoA engages multiple effector pathways through structurally independent interfaces.\",\n      \"evidence\": \"Yeast two-hybrid with RhoA/Rac chimeras, in vitro ligand overlay with ROCK, functional stress fiber assay in HeLa cells with Y-27632\",\n      \"pmids\": [\"9668072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structures of RhoA–effector complexes had not been solved\", \"Whether the two surfaces cooperate or are mutually exclusive in vivo was unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Citron kinase was placed at the cleavage furrow and midbody as a RhoA effector whose truncation causes multinucleation, providing the first evidence that RhoA signals through effectors beyond ROCK during cytokinesis.\",\n      \"evidence\": \"Immunolocalization plus dominant-negative truncation overexpression causing multinucleation\",\n      \"pmids\": [\"10816250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab overexpression study; loss-of-function (siRNA/knockout) confirmation was lacking\", \"Relationship between citron and ROCK at the furrow was not delineated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstration that RhoA induces stress fibers and focal adhesions and is required downstream of Ras for transformation established RhoA as a central cytoskeletal organizer with oncogenic relevance.\",\n      \"evidence\": \"Dominant-negative N19-RhoA and constitutively active V14-RhoA expression in fibroblasts; focus-formation assays\",\n      \"pmids\": [\"8524848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking RhoA to transcriptional transformation was unresolved\", \"Whether RhoA contribution to transformation is solely cytoskeletal was unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"ROCK was shown to drive Ca²⁺-independent contraction by phosphorylating and inhibiting myosin phosphatase, thereby sustaining MLC phosphorylation—defining the core RhoA→ROCK→myosin phosphatase→MLC contractility axis.\",\n      \"evidence\": \"Pharmacological ROCK inhibition (Y-27632), in vitro kinase and phosphatase activity assays, smooth muscle contraction measurements\",\n      \"pmids\": [\"11165670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of direct MLC phosphorylation by ROCK vs. phosphatase inhibition were not quantified\", \"ROCK isoform-specific roles were unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Cadherin-mediated cell–cell adhesion was found to suppress RhoA while activating Rac1, establishing a receptor-level input that toggles the Rho–Rac balance upon cell contact.\",\n      \"evidence\": \"Rho-GTP pulldown, calcium-switch experiments, cadherin cytoplasmic domain deletion, function-blocking antibodies\",\n      \"pmids\": [\"11457821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The GEF or GAP mediating cadherin-to-RhoA inhibition was not identified\", \"Whether p120-catenin mediates this effect was not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Cardiac-specific sequestration of Rho GTPases by RhoGDIα overexpression caused defective heart morphogenesis and proliferation arrest, demonstrating an essential in vivo requirement for Rho activity in organ development.\",\n      \"evidence\": \"Transgenic mouse with cardiac-specific RhoGDIα; RhoA/Rac1/Cdc42 activity assays, proliferation and cell-cycle markers\",\n      \"pmids\": [\"11923206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pan-Rho inhibition by GDI did not distinguish individual GTPase contributions\", \"Whether the proliferation defect is direct or secondary to contractile failure was unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that Rac-generated ROS inhibit LMW-PTP, thereby activating p190RhoGAP and inactivating RhoA, revealed a redox-mediated antagonism between Rac and Rho that governs cell spreading.\",\n      \"evidence\": \"Co-immunoprecipitation, ROS measurement, phosphatase activity assays, dominant-negative/constitutively active mutants, cell spreading\",\n      \"pmids\": [\"12598902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the ROS–p190RhoGAP axis operates in vivo during migration was untested\", \"Quantitative thresholds of ROS required for RhoA inactivation were unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"p75NTR was shown to displace RhoA from RhoGDI upon myelin ligand binding, explaining how Nogo and MAG activate RhoA to inhibit axon regeneration and defining a receptor-level mechanism of GDI displacement.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation and pulldown of p75NTR–RhoGDI, peptide inhibition, neurite outgrowth assays\",\n      \"pmids\": [\"12692556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GDI displacement releases RhoA for GEF-mediated activation or produces constitutive activation was unclear\", \"In vivo validation in spinal cord injury models was pending\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Integrin–fibronectin engagement was shown to be required for ROCK to phosphorylate MLC downstream of active RhoA, revealing an adhesion-dependent permissive gate in the Rho–ROCK–myosin pathway.\",\n      \"evidence\": \"Phospho-MLC and phospho-MYPT1 antibodies, constitutively active RhoA and ROCK, cell detachment/reattachment on fibronectin vs. poly-L-lysine\",\n      \"pmids\": [\"15226371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of integrin-dependent permissiveness for ROCK was not identified\", \"Whether integrin signaling acts on ROCK localization or substrate accessibility was unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Spatial restriction of active RhoA to the equatorial cortex during cytokinesis was directly visualized, establishing that RhoA zone geometry dictates contractile ring positioning.\",\n      \"evidence\": \"Active RhoA biosensors (FRET/GST-RBD), live-cell imaging, dominant-negative/constitutively active mutants\",\n      \"pmids\": [\"16243528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism that creates and maintains the sharp RhoA zone boundaries was not defined\", \"Relative contributions of local activation vs. lateral diffusion were unquantified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Rap1 was found to activate RA-RhoGAP toward RhoA via direct RA-domain binding, promoting neurite outgrowth, establishing Rap1 as an indirect negative regulator of RhoA in neuronal morphogenesis.\",\n      \"evidence\": \"In vitro GAP assay, GTP-Rap1 pulldown, siRNA knockdown, neurite outgrowth assay\",\n      \"pmids\": [\"16014623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RA-RhoGAP targets RhoA selectively in neurons vs. other cell types was unclear\", \"Upstream activators of Rap1 in this context were not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"ROCK phosphorylation of FilGAP was shown to stimulate Rac inactivation, defining a RhoA→ROCK→FilGAP→Rac cascade that explains mutual antagonism between RhoA-driven contraction and Rac-driven protrusion.\",\n      \"evidence\": \"In vitro ROCK kinase assay, siRNA knockdown of FilGAP, ROCK inhibitor Y-27632, cell spreading/bleb assays\",\n      \"pmids\": [\"16862148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FilGAP is the sole mediator of Rho–Rac antagonism was unknown\", \"Spatial regulation of FilGAP relative to the Rho activity zone was not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"p0071 was placed at the midbody where it binds both RhoA and the GEF Ect2, and its depletion causes multinucleation, establishing a scaffold that locally couples GEF activity to RhoA during cytokinesis.\",\n      \"evidence\": \"Reciprocal co-IP of p0071 with RhoA and Ect2, siRNA knockdown causing cytokinesis failure, immunofluorescence at midbody\",\n      \"pmids\": [\"17115030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p0071 activates or merely localizes Ect2 was not distinguished\", \"Redundancy with other armadillo proteins was not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"GEF-H1 was identified as the GEF activating RhoA during junctional disassembly, with ROCK-II (not ROCK-I) as the relevant downstream effector, revealing isoform-specific pathway wiring at epithelial junctions.\",\n      \"evidence\": \"siRNA knockdown of GEF-H1, ROCK-I, ROCK-II; RhoA activity pulldown; calcium depletion junctional disassembly assay\",\n      \"pmids\": [\"17596509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of GEF-H1 release from tight junctions upon calcium depletion was not defined\", \"Whether ROCK-II specificity reflects localization or substrate preference was unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"MgcRacGAP GAP activity was shown to be required to focus the equatorial RhoA zone, demonstrating that continuous GTPase cycling—not just activation—shapes the spatial signal during cytokinesis.\",\n      \"evidence\": \"Point mutation of MgcRacGAP catalytic residue combined with live RhoA biosensor imaging in Xenopus embryos\",\n      \"pmids\": [\"19060892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Ect2 GEF and MgcRacGAP activities are quantitatively balanced was not measured\", \"Whether the same flux mechanism operates in mammalian somatic cells was not confirmed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery of FAM65A as a Rho effector linking active RhoA/B/C to the CCM3–MST3/MST4 kinase complex at the Golgi revealed a non-contractile Rho output that controls Golgi polarity and directional migration.\",\n      \"evidence\": \"Co-IP/pulldown of FAM65A with active Rho, siRNA knockdown, MST kinase activity assay, Golgi reorientation and migration assays\",\n      \"pmids\": [\"27807006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates of MST3/4 downstream of FAM65A that execute Golgi reorientation were not identified\", \"Whether this pathway operates in vivo during tissue morphogenesis was untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the quantitative parameters governing RhoA GEF–GAP flux at the cytokinetic zone, the structural basis of dual-surface effector recognition, and how multiple upstream inputs (cadherins, integrins, p75NTR, ROS) are integrated in space and time to set RhoA activity levels in migrating and dividing cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No quantitative model of GEF–GAP flux parameters at the equatorial zone\", \"No full structural model of the RhoA dual-surface effector engagement\", \"Integration logic for simultaneous cadherin, integrin, and receptor tyrosine kinase inputs on RhoA is undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 8, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 7, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 18, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 12]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8, 9, 15, 16, 22]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [4, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ROCK1\",\n      \"ROCK2\",\n      \"CIT\",\n      \"FAM65A\",\n      \"ARHGDIA\",\n      \"ARHGAP35\",\n      \"ECT2\",\n      \"RACGAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Rhodopsin (RHO) is a light-activated G protein–coupled receptor in rod photoreceptors that initiates the visual transduction cascade by coupling photon absorption to transducin activation. The 11-cis-retinal chromophore is held inactive by a Lys296–Glu113 salt bridge; photoisomerization breaks this constraint, driving stepwise TM5–TM6 rearrangement that opens a cytoplasmic crevice into which the Gαt C-terminal helix inserts to catalyze GDP/GTP exchange [PMID:1356370, PMID:19836958, PMID:29899450]. Signal termination proceeds through rhodopsin kinase phosphorylation of C-terminal residues T336/S338, which form an intermolecular β-sheet with arrestin N-terminal β-strands, defining a conserved phosphorylation code for arrestin recruitment [PMID:28753425, PMID:26200343]. Mutations in RHO cause autosomal dominant retinitis pigmentosa—with class II transmembrane/extracellular-domain mutations producing ER-retained misfolded protein, C-terminal mutations disrupting outer segment targeting, and constitutively activating mutations (e.g., A292E, G90D) causing congenital night blindness [PMID:2137202, PMID:8253795, PMID:8358437, PMID:7523628].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Cloning and sequencing of the human RHO gene established its exon-intron organization and 348-residue primary structure, providing the molecular foundation for all subsequent structure–function studies.\",\n      \"evidence\": \"Gene isolation and full nucleotide sequencing of human rhodopsin\",\n      \"pmids\": [\"6589631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional assays performed\", \"Three-dimensional structure unknown at this stage\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of palmitoylation at Cys-322/Cys-323 revealed a post-translational lipid anchor that tethers the cytoplasmic tail to the membrane, defining a structural feature later recognized as helix 8.\",\n      \"evidence\": \"Biochemical peptide fractionation and chemical characterization of bovine rhodopsin C-terminal fragment\",\n      \"pmids\": [\"3350146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of palmitoylation for signaling or trafficking not tested\", \"Human rhodopsin palmitoylation inferred from bovine data\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Discovery of the Pro23His mutation and additional mutations at codons 58 and 347 as causes of autosomal dominant retinitis pigmentosa established RHO as the first identified ADRP gene and raised the question of how diverse mutations in a single receptor cause photoreceptor degeneration.\",\n      \"evidence\": \"PCR-based mutation screening in ADRP patient cohorts with cosegregation analysis\",\n      \"pmids\": [\"2137202\", \"2215617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of degeneration for each mutation unknown\", \"No biochemical classification of mutation effects yet\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mutagenesis of cytoplasmic loops demonstrated that distinct regions mediate transducin binding versus GDP/GTP exchange, dissecting the receptor–G protein coupling interface for the first time.\",\n      \"evidence\": \"Site-directed mutagenesis with flash photolysis and GTPase activity assays in vitro\",\n      \"pmids\": [\"2218504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of loop–transducin contact not resolved\", \"Role of helix 8 and C-terminus in G protein coupling not addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating that disruption of the Lys296–Glu113 salt bridge causes constitutive transducin activation established the molecular constraint that holds dark-state rhodopsin inactive—a foundational insight for understanding both normal activation and gain-of-function disease mutations.\",\n      \"evidence\": \"Site-directed mutagenesis of K296 and E113 with in vitro transducin activation assays\",\n      \"pmids\": [\"1356370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural dynamics of salt bridge breakage during activation not visualized\", \"Whether other interhelical contacts also restrain activation not addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Transgenic P23H mice reproduced human ADRP with dose-dependent photoreceptor degeneration, providing the first in vivo validation that a specific rhodopsin mutation is sufficient to cause the disease.\",\n      \"evidence\": \"Multiple transgenic mouse lines with graded expression; histology and ERG\",\n      \"pmids\": [\"1418997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular mechanism of degeneration (misfolding, ER stress, proteasome impairment) not yet identified\", \"Wild-type overexpression also caused degeneration, complicating interpretation\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Systematic biochemical analysis of 21 ADRP mutants established two mechanistic classes: class II mutations (transmembrane/extracellular) cause misfolding and ER retention, while class I mutations (cytoplasmic/C-terminal) fold normally but affect function or trafficking, providing a framework that guided subsequent therapeutic strategies.\",\n      \"evidence\": \"HEK293S cell expression, retinal regeneration assay, immunofluorescence localization\",\n      \"pmids\": [\"8253795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether class II mutants trigger UPR or specific degradation pathways not tested\", \"In vivo relevance of class assignments not yet confirmed\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"The A292E mutation was shown to constitutively activate transducin without chromophore, explaining congenital stationary night blindness as a gain-of-function mechanism distinct from the loss-of-function RP mutations.\",\n      \"evidence\": \"In vitro transducin activation assay with recombinant A292E opsin ± chromophore\",\n      \"pmids\": [\"8358437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of A292E constitutive activity not resolved\", \"Whether other night blindness mutations share this mechanism not fully explored\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"G90D was found to constitutively activate opsin by functionally substituting for the Glu-113 counterion, unifying the night-blindness mutations under a common salt-bridge disruption mechanism; separately, Q344ter truncation demonstrated that the C-terminus contains an outer segment targeting signal.\",\n      \"evidence\": \"Mutagenesis with suppressor analysis for G90D; transgenic mice with confocal immunofluorescence for Q344ter\",\n      \"pmids\": [\"8107847\", \"7523628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the C-terminal targeting machinery unknown\", \"Whether mislocalization alone is sufficient for degeneration not established\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"P347S transgenic mice showed rhodopsin-laden extracellular vesicles at the inner/outer segment junction, directly demonstrating that C-terminal mutations cause defective vectorial transport rather than protein misfolding.\",\n      \"evidence\": \"Transgenic mice with ultrastructural immunocytochemistry and confocal microscopy\",\n      \"pmids\": [\"8943080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery mediating C-terminal-dependent transport not identified\", \"Contribution of vesicle shedding to photoreceptor death not quantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"P23H rhodopsin was shown to form high-molecular-weight aggregates in aggresomes and impair proteasome function, identifying proteostasis collapse as a specific toxic mechanism for class II misfolding mutants.\",\n      \"evidence\": \"FRET-based aggregation detection, immunofluorescence of aggresomes, proteasome activity assays in transfected cells\",\n      \"pmids\": [\"12091393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether proteasome impairment is the primary cause of photoreceptor death in vivo not established\", \"Role of autophagy as alternative clearance pathway not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mutagenesis of the NPxxY(x)5,6F motif revealed that the Y306–F313 interaction must break during Meta II formation but is separately required for G protein activation, defining helix 8 realignment as a distinct mechanistic step in receptor signaling.\",\n      \"evidence\": \"Alanine mutagenesis and disulfide trapping with UV-vis spectroscopy and transducin activation assays\",\n      \"pmids\": [\"12601165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of helix 8 motion not captured at atomic resolution\", \"Whether helix 8 rearrangement also controls arrestin recruitment not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Integration of crystal structures and biochemical data defined the complete activation cascade: retinal photoisomerization drives TM5–TM6 opening of a cytoplasmic crevice into which the Gα C-terminal helix inserts as a transmission rod to the nucleotide binding site, resolving the structural mechanism of GDP/GTP exchange.\",\n      \"evidence\": \"Synthesis of high-resolution crystal structures with biochemical activation studies\",\n      \"pmids\": [\"19836958\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full dynamics of the activation intermediate states not captured\", \"Structural basis of kinetic selectivity for transducin over other G proteins not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The first crystal structure of the rhodopsin–arrestin complex revealed that TM7 and helix 8 form the primary arrestin recruitment interface, and arrestin undergoes a ~20° inter-domain rotation to accommodate rhodopsin's second intracellular loop, establishing the structural basis of signal termination.\",\n      \"evidence\": \"Serial femtosecond XFEL crystallography with mutagenesis validation\",\n      \"pmids\": [\"26200343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the pre-activated arrestin used captures the physiological binding mode debated\", \"Membrane context and lipid contributions absent\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Higher-resolution XFEL structure defined a phosphorylation code: phospho-T336, phospho-S338, and E341 of rhodopsin form an intermolecular β-sheet with three positively charged arrestin pockets, a mechanism generalizable across GPCRs.\",\n      \"evidence\": \"XFEL crystallography with phosphorylation-site identification and cross-GPCR mutagenesis validation\",\n      \"pmids\": [\"28753425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full combinatorial phosphorylation code (barcode) not exhaustively mapped\", \"Kinetic contribution of individual phosphorylation sites to arrestin affinity in vivo not determined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Cryo-EM structure of activated rhodopsin bound to Gi revealed unique structural signatures distinguishing Gi, Gs, and arrestin coupling, addressing the long-standing question of how a single GPCR architecture selects among effectors.\",\n      \"evidence\": \"Cryo-EM structure determination with comparative structural analysis\",\n      \"pmids\": [\"29899450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transducin (Gt)-specific complex structure not yet determined at comparable resolution\", \"How membrane composition modulates coupling selectivity remains unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the high-resolution structure of the native rhodopsin–transducin complex in a membrane environment, the precise contribution of each C-terminal phosphorylation site to arrestin affinity in vivo, and the mechanistic link between P23H aggregation/proteasome impairment and photoreceptor cell death.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No native rhodopsin–transducin complex structure at high resolution\", \"In vivo phosphorylation barcode not fully mapped\", \"Causal pathway from protein aggregation to rod cell death not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 7, 11, 12, 18, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 7, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9, 13, 14]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [9, 15]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [13, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 7, 11, 12, 16, 18, 20, 21, 22]},\n      {\"term_id\": \"R-HSA-9709957\", \"supporting_discovery_ids\": [7, 11, 12, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 5, 6, 8, 9, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAT1\",\n      \"SAG\",\n      \"GRK1\",\n      \"GNB1\",\n      \"GNAI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}